Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.51 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538121 | 0.87 | KDM4E (0.50) | ALDH1A1HPGDTRPC3TRPC6KDM4E | |
| SCHEMBL3540182 | 0.87 | ALDH1A1 (0.60) | ALDH1A1HPGDTRPC3TRPC6KDM4E | |
| SCHEMBL4973267 | 0.86 | RAB9A (0.54) | ALDH1A1TRPC3TRPC6KDM4ERAB9A | |
| SCHEMBL3536201 | 0.85 | PIN1 (0.51) | ALDH1A1TRPC3TRPC6RAB9ATLR7 | |
| SCHEMBL3537356 | 0.83 | TLR7 (0.48) | ALDH1A1TRPC3TRPC6KDM4ETLR7 | |
| SCHEMBL3957201 | 0.78 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4ERAB9ATLR7 | |
| SCHEMBL20988524 | 0.77 | TLR7 (0.63) | ALDH1A1HPGDKDM4ERAB9ATLR7 | |
| SCHEMBL29999179 | 0.76 | TLR7 (0.61) | ALDH1A1HPGDKDM4ERAB9ATLR7 | |
| SCHEMBL911120 | 0.75 | MGLL (0.47) | ALDH1A1HPGDTRPC3TRPC6KDM4E | |
| SCHEMBL4971750 | 0.75 | HTR2C (0.64) | ALDH1A1HPGDTRPC3TRPC6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979335-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | claimed |
| WO-2007082808-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | claimed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1979335-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007082808-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007082808-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | ALDH1A1 707/4885HPGD 1113/4885TRPC3 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.